Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. (NASDAQ: AGEN) generates a steady stream of news centered on its immuno-oncology pipeline, with particular focus on the botensilimab (BOT) and balstilimab (BAL) combination. As a Lexington, Massachusetts-based biological products manufacturer focused on cancer immunotherapy, the company’s updates frequently highlight progress in clinical trials, early-access frameworks and strategic collaborations.
Many recent headlines relate to BOT+BAL’s performance in advanced solid tumors. Agenus reports data from the C-800-01 Phase 1b trial, which evaluates the combination across multiple refractory cancers, and from the global BATTMAN CO.33 Phase 3 trial in microsatellite-stable colorectal cancer conducted with the Canadian Cancer Trials Group and international academic partners. News coverage also includes peer-reviewed publications, such as results in treatment-refractory ovarian cancer, and presentations at major oncology congresses.
Another major theme in Agenus news is patient access. The company has announced that France’s medicines agency authorized a national Autorisation d’Accès Compassionnel (AAC) protocol for BOT+BAL, enabling fully reimbursed hospital-based access for eligible patients with microsatellite-stable metastatic colorectal cancer, certain ovarian cancers and soft-tissue sarcomas. Additional stories describe named-patient and early-access programs in other geographies where regulations allow.
Strategic and corporate developments also feature prominently. Agenus has disclosed a collaboration with Zydus Lifesciences involving the sale of biologics manufacturing facilities in California, an equity investment in Agenus, and an exclusive license for BOT and BAL in India and Sri Lanka, along with the creation of Zylidac Bio LLC to house the acquired U.S. manufacturing assets. Investors following AGEN news can expect updates on clinical milestones, regulatory interactions, early-access expansions, manufacturing partnerships and periodic financial and corporate communications.
Agenus (Nasdaq: AGEN) will present investigator‑initiated Phase II data of a novel triplet immunotherapy—botensilimab (BOT) + balstilimab (BAL) with agenT‑797—in PD‑1 refractory gastroesophageal cancer (GEC) at AACR 2026.
Presentation is April 20, 2026 (2:00–5:00 PM PT / 5:00–8:00 PM EDT), Poster Section 52, Abstract CT166. Data aim to inform immune modulation, sequencing, and durability of response in checkpoint‑refractory tumors.
Agenus (Nasdaq: AGEN) announced enrollment of the first patient in the global Phase 3 BATTMAN (CO.33) trial (NCT07152821) testing botensilimab (BOT) + balstilimab (BAL) versus best supportive care in refractory, unresectable MSS/pMMR metastatic colorectal cancer.
The registrational study plans to enroll approximately 830 patients across >100 sites in Canada, France, Australia and New Zealand through cooperative groups CCTG, GI Cancer Trials and PRODIGE.
Agenus (Nasdaq: AGEN) will host a stakeholder webcast on March 31, 2026 at 4:30 p.m. ET to review clinical progress of botensilimab + balstilimab (BOT+BAL), patient access programs, development across tumor types, and 2026 priorities. The session includes remarks by CEO Garo Armen and a live Q&A.
Speakers include the CEO, CMO Steven O’Day, and Head of Medical Affairs Kamel Djazouli; registration and question-submission links are provided for live participation.
Agenus (Nasdaq: AGEN) announced that preliminary Phase 2 results from an investigator-sponsored study of botensilimab (BOT) plus balstilimab (BAL) in first-line microsatellite stable metastatic colorectal cancer (MSS mCRC) will be presented at AACR 2026 (April 18–23) in San Diego.
The BBOpCo study (NCT06268015) evaluates BOT+BAL in MSS mCRC patients without liver, bone, or brain metastases, aiming to introduce immunotherapy earlier and reduce reliance on cytotoxic chemotherapy.
Agenus (Nasdaq: AGEN) reported 2025 results, recognizing initial $4.2M in pre-commercial BOT+BAL revenues from early access programs and initiating the global Phase 3 BATTMAN trial in refractory MSS metastatic colorectal cancer.
The company secured a $91M upfront collaboration with Zydus and triggered a $20M contingent payment to strengthen manufacturing and balance sheet.
Agenus (Nasdaq: AGEN) triggered a $20 million contingent payment under its collaboration with Zydus Lifesciences to fund contracted CMC and production work for botensilimab (BOT) and balstilimab (BAL). The activities support BLA/MAA readiness, expanded clinical and paid access supply, and U.S.-based manufacturing capacity.
Agenus (Nasdaq: AGEN) will release its Q4 and year-end 2025 financial results before the market opens on Monday, March 16, 2026. The company will host a stakeholder briefing webcast in late March to spotlight strategic plans, data milestones and updates on global botensilimab (BOT) and balstilimab (BAL) development.
Agenus (Nasdaq: AGEN) presented translational and clinical biomarker data from its Phase 1b C-800-01 trial of botensilimab (BOT) plus balstilimab (BAL) showing activity in immunologically “cold” tumors.
In 341 efficacy-evaluable patients (data cutoff Dec 13, 2025) overall response rate was 17%, clinical benefit rate 26%, median overall survival 17.2 months and 24‑month OS rate 38%. Integrated blood and tumor markers improved survival stratification (C‑index up to 0.73), particularly in MSS metastatic colorectal cancer.
Agenus (Nasdaq: AGEN) will present new translational and clinical biomarker analyses from its botensilimab (BOT) program at the AACR‑IO Conference on February 19, 2026. The poster examines how systemic inflammatory markers, tumor microenvironment immune activity, and peripheral immune cell states relate to outcomes in immunologically "cold," treatment‑refractory tumors treated with BOT or BOT+BAL.
Presentation is scheduled for Poster Session B, Thursday, February 19, 2026, 12:15–3:15 PM PT in the JW Marriott Platinum Ballroom; Chloe Delepine PhD is the presenting author.
Agenus (Nasdaq: AGEN) said it has expanded its global Medical Affairs infrastructure to support growing physician requests for authorized access to the investigational combination botensilimab plus balstilimab (BOT+BAL).
The company highlighted increasing use of regulatory-authorized early access pathways, including France’s AAC framework (now reimbursed for three tumor types) and paid named-patient programs in multiple countries where permitted, with patients already treated under these programs.
Medical Affairs expansion aims to support compliant access, pharmacovigilance, safety monitoring, and real-world data collection; BOT+BAL remains investigational and is limited to clinical trials in the United States.